Human MetapneumovirusPhase 1NCT06546423
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
A Phase 1 study testing B/HPIV3/HMPV-PreF-A vaccine and B/HPIV3/HMPV-F-B365 vaccine in people with Human Metapneumovirus and Human Parainfluenza Virus Type 3, run by National Institute of Allergy and Infectious Diseases (NIAID) at 4 sites in United States.
Trial summary
HPIV3 and HMPV are viruses that can cause breathing problems in children. The goal of this clinical trial is to look at the safety of 2 experimental HPIV3/HMPV vaccines in HPIV3-seropositive children ≥ 24 months to < 60 months of age. Read more about this study
- Who is it for?
- Ages 24 to 59 monthsHealthy volunteers can take part
- Conditions the study is for
- Human Metapneumovirus, Human Parainfluenza Virus Type 3
- What is being tested?
- B/HPIV3/HMPV-PreF-A vaccine and B/HPIV3/HMPV-F-B365 vaccine
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 4 sitesUnited States
- Study dates
- 12 Jul 2024to 4 Jun 2025
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 59 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- ≥24 months of age and <60 months of age at the time of inoculation
- HAI Screening for HPIV3-neutralizing antibody is obtained within the calendar year of inoculation
- Seropositive for HPIV3 antibody, defined as serum HPIV3 HAI titer >1:8
- Pre-inoculation serum sample for HPIV3-neutralizing antibody specimen is obtained no more than 42 days prior to inoculation
- In good health based on review of the medical record, history, and physical examination at the time of inoculation
- Received routine immunizations appropriate for age based on the Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger
Show all 9Show fewer
- Growing normally for age as demonstrated on a World Health Organization (WHO) growth chart, AND has a current height and weight above the 3rd percentile for age
- Expected to be available for the duration of the study
- Parent/guardian is willing and able to provide written informed consent
Who cannot join
- <24 months of age and >60 months of age at the time of inoculation.
- Born at less than 34 weeks gestation
- Maternal history of a positive HIV test before or during pregnancy.
- Evidence of chronic disease
- Known or suspected infection or impairment of immunological functions
- Bone marrow/solid organ transplant recipient
Show all 48Show fewer
- Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
- Suspected or documented developmental disorder, delay, or other developmental problem
- Cardiac abnormality requiring treatment
- Lung disease or reactive airway disease
- More than one episode of medically diagnosed wheezing in the first year of life
- Wheezing episode or received bronchodilator therapy or racemic epinephrine within the past 12 months
- Wheezing episode or received bronchodilator therapy after the age of 12 months
- Previous receipt of supplemental oxygen therapy in a home setting
- Previous receipt of an investigational HPIV3 or HMPV vaccine
- Previous receipt or planned administration of human immunoglobulin within the past 6 months. Receipt of licensed monoclonal antibody products for passive prophylaxis against RSV (e.g., nirsevimab) within the past 6 months is not a cause for exclusion
- Previous receipt of any blood products within the past 6 months.
- Previous anaphylactic reaction
- Previous vaccine-associated adverse reaction that was Grade 3 or above.
- Known hypersensitivity to any study product component
- Member of a household that contains an infant who is less than 12 months of age at the date of inoculation through the 10th day after inoculation
- Member of a household that, at the date of inoculation through the 10th day after inoculation, contains an immunocompromised individual including but not limited to:
- a person who is HIV-infected
- a person who has cancer and has received chemotherapy within the 12 months prior to enrollment
- a person living with a solid organ or bone marrow transplant
- Attends a daycare facility that does not separate children by age and contains a child <12 months of age at the date of inoculation through the 10th day after inoculation
- Receipt of any of the following prior to enrollment:
- inactivated influenza vaccine within 3 days prior, or
- any other inactivated vaccine, messenger RNA (mRNA) vaccine, or live-attenuated rotavirus vaccine within the 14 days prior, or
- any live vaccine, other than rotavirus vaccine, within the 28 days prior, or
- another investigational vaccine or investigational drug within 28 days prior, or
- salicylate (aspirin) or salicylate-containing products within the past 28 days
- Scheduled administration of any of the following after planned inoculation:
- inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or
- any live vaccine other than rotavirus within the 28 days after, or
- any salicylate or salicylate-containing products within the 28 days after, or
- another investigational vaccine or investigational drug in the 56 days after
- Receipt of any of the following medications within 3 days prior to study enrollment:
- systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or
- intranasal medications, or
- other prescription medications except the permitted concomitant medications listed below
- Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents
- Any of the following events at the time of enrollment:
- fever (temporal or rectal temperature of ≥100.4°F), or
- upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis), or
- nasal congestion significant enough to interfere with successful inoculation, or
- otitis media, or
- contact with a person diagnosed with COVID-19 disease or active SARS-CoV-2 infection within the preceding 10 days
Trial locations and contacts
4 sites in 1 country.
United States4 sites
CIR - Rangos, Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 21205
CIR South
Columbia, Maryland, 21045
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
University of Rochester Medical Center
Rochester, New York, 14642
About this study
Official title: Phase I Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vectored Vaccines Expressing the Fusion Glycoprotein of Human Metapneumovirus (HMPV), Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
HPIV3 and HMPV are viruses that can cause breathing problems in children. The goal of this clinical trial is to look at the safety of 2 experimental HPIV3/HMPV vaccines in HPIV3-seropositive children ≥ 24 months to < 60 months of age. Children will receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, or placebo, and participants will not know which study product they have received.
The main goals of the study are to find out whether these vaccines are well-tolerated and infectious in HPIV3-seropositive children.
Read more
The general procedures include daily temperature measurements and daily contact with the participant for the first 28 days, giving a single dose of one of the 2 study vaccines or placebo delivered by nasal sprayer, about 9 in-person visits, a physical examination, 7 clinical assessments, 2 blood samples, 9 nasal swabs and monthly contacts with the participant between Days 29-180.
Additional visits may occur if the child has a respiratory illness, fever, or ear infections. The illness visit will include a nasal swab and a clinical assessment.
Read the detailed description
This is a blinded, randomized, placebo-controlled study design will be used to evaluate the safety and immunogenicity of the study product in HPIV3-seropositive participants. The study will be performed in approximately 25 HPIV3-seropositive children ≥ 24 months to < 60 months of age. Subjects will be block randomized to receive a single dose of 10^5.6 PFU of B/HPIV3/HMPV-PreF-A, 10^5.6 PFU of B/HPIV3/HMPV-F-B365, or placebo in a 2:2:1 ratio. Enrollment will be continuous unless stopping rules are met or other safety concerns occur. During the enrollment period, the Data and Safety Monitoring Board (DSMB) will perform unblinded safety reviews. After completion of the Day 28 visit of the last participant, an unblinded review of all participants will be performed by the DSMB.
The first 28 days after inoculation are considered the Acute Phase of the study, and the participants' parents/guardians will be contacted daily during the Acute Phase. These contacts will consist either of an in-person evaluation of interim medical history, clinical assessment, and nasal swab, or an interim medical history conducted by a mutually agreed upon communication method. If a child develops a respiratory or febrile illness or otitis media during the acute phase, an in-person evaluation will be performed. During the Acute Phase, the participants will be evaluated for adverse events (AEs) or serious adverse events (SAEs). Between Days 29 and 180 parents/guardians will be asked to contact study staff to report Medically Attended Adverse Events (MAAEs), which will be reported per protocol. Between days 29-180, study staff will contact the participants' parents/guardians monthly and on Day 180 (±7 days) after inoculation to capture any previously unreported MAAEs.
Clinical assessments will be completed and nasal swabs will be obtained on study Days 0, 3, 4, 5, 6, 7, 10, 14 and 28 and whenever febrile or respiratory illnesses or otitis media (solicited AEs) are reported during the first 28 days following inoculation. The nasal swab will be tested for vaccine virus, for respiratory pathogens that are considered adventitious agents, including wild-type HPIV3 and HMPV, and for mucosal IgG and IgA antibody as listed in the schedule of events.
- Being tested
- B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
B/HPIV3/HMPV-PreF-A vaccineBiological
B/HPIV3/HMPV-PreF-A is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-PreF-A vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10^6.7 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10^5.6 PFU in a 0.2 mL volume.
B/HPIV3/HMPV-F-B365 vaccineBiological
B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-F-B365 vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10^6.3 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10^5.6 PFU in a 0.2 mL volume.
PlaceboDrug
Also called Lactated Ringer's Solution for Injection
Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
| Study group | Role | What they receive |
|---|---|---|
| B/HPIV3/HMPV-PreF-A vaccine | Active comparator | A single dose of intranasal B/HPIV3/HMPV-PreF-A will be administered by a Vax300 VaxINator atomization device. Receives: Biological: B/HPIV3/HMPV-PreF-A vaccine |
| B/HPIV3/HMPV-F-B365 vaccine | Active comparator | A single dose of intranasal B/HPIV3/HMPV-F-B365 will be administered by a Vax300 VaxINator atomization device. Receives: Biological: B/HPIV3/HMPV-F-B365 vaccine |
| Placebo | Placebo comparator | A single dose of intranasal Lactated Ringer's Solution for Injection will be administered by a Vax300 VaxINator atomization device. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade
Solicited adverse events include fever; otitis media; upper respiratory illness (URI); lower respiratory illness (LRI) and cough (without LRI) as defined in Appendix II of the protocol document. The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each solicited AE category, and that is in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 5-death) following protocol-defined grading system outlined in Table 13 and Table 14 in the protocol document. Details regarding LRIs will be noted in Primary Outcome Measure #2.
Measured: Day 0 through Day 28
Frequency of Lower Respiratory Illness (LRIs) by Grade
LRI may include wheezing, pneumonia, laryngotracheobronchitis (croup), rhonchi and rales as defined in Appendix II of the protocol document. A participant was only counted once in each LRI category, and that is in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 5-death) following protocol-defined grading system outlined in Table 13 in the protocol document.
Measured: Measured through Day 28
Percentage of Vaccinees With a ≥4-fold Rise in HPIV3 Serum Neutralizing Antibody Titer
Serum HPIV3-neutralizing antibody titers were assessed by 60% HPIV3-plaque reduction neutralization titer (HPIV3-PRNT) assay. Antibody responses were defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points.
Measured: Measured at Day 0 and Day 28
Percentages of Vaccinees With a ≥4-fold Rise in HMPV-neutralizing Serum Antibody Titers
Serum HMPV-neutralizing antibody titers were assessed by 60% HMPV-plaque reduction neutralization titer (HMPV-PRNT) assay. Antibody responses were defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points.
Measured: Measured at Day 0 and Day 28
Peak Titers of Vaccine Virus Shed
This is the highest value per participant of the titer of vaccine virus shed. It was measured by RT-qPCR. For the purposes of calculation, peak titers of 1.7 log10 copy number, which is the lower limit of detection of the RT-qPCR assay, were assigned to qPCR negative samples. Note that only 1 participant who received the B/HPIV3/HMPV-PreF-A vaccine and only 1 participant that received the B/HPIV3/HMPV-F-B365 vaccine shed vaccine virus.
Measured: Measured study days 0-28
Number of Vaccinees Infected With Vaccine Virus
Infection with vaccine virus is determined by shedding of vaccine virus detected by immunoplaque assay and/or RT-qPCR, and/or ≥4 fold rise in HPIV3 or HMPV-specific serum antibodies, detected by neutralizing antibody assay or ELISA from study entry to Study Day 28
Measured: Measured through Day 28
Secondary outcomes (2)
Frequency and Severity of Medically Attended Adverse Events (MAAEs) by Grade
The number of participants who had medically attended illness (solicited and unsolicited adverse events). A participant was only counted once in each AE category, and that is in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 5-death) following protocol-defined grading system outlined in Table 13 and Table 14 in the protocol document.
Measured: Measured from Day 29 through Day 180 (Observation Period)
Number of Participants Who Experienced Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is an AE, whether considered related to the study product or not, that:
Results in death during the period of protocol-defined surveillance; Is life threatening: defined as an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death were it more severe; Requires inpatient hospitalization (or prolongation of existing hospitalization): defined as at least an overnight stay in the hospital or emergency ward for treatment that would have been inappropriate if administered in the outpatient setting; Results in a persistent or significant disability/incapacity; Is a congenital anomaly or birth defect, OR Is an important medical event that may not be immediately life threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
Measured: Measured Day 0 through Day 180 after inoculation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2024
- Study start12 Jul 2024
- Primary completion4 Jun 2025
- Study completion4 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Human MetapneumovirusStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized to receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine or placebo in a 2:2:1 ratio.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Collaborators
- Johns Hopkins Bloomberg School of Public Health, Vanderbilt University Medical Center, University of Rochester
- Responsible party
- Sponsor
- Investigators
- Ruth Karron, M.D., Principal investigator, Center for Immunization Research, JHBSPH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06546423
- Sponsor's protocol ID
- CIR363
- Status last verified
- Jun 2026
- First submitted
- 6 Aug 2024
- Last updated
- 18 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers may request access to IPD that underlie results in a publication. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.